Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US
https://www.businesswire.com/news/home/20250117223765/en/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.